“…This is consistent with the repression of BTG2 expression in several human tumors including the breast, thymus, prostate and kidney (Lim et al, 1995;Ficazzola et al, 2001;Kawakubo et al, 2004Kawakubo et al, , 2006Struckmann et al, 2004). Moreover, expression of BTG2 in a mouse model for medulloblastoma suppressed the formation of tumors (Farioli-Vecchioli et al, 2007). Although BTG2 has been shown to interact with transcription factors (Prevot et al, 2000), promote mRNA deadenylation and turnover (Mauxion et al, 2008(Mauxion et al, , 2009) and modulate signaling through its interaction with signaling molecules (Park et al, 2004;Hong et al, 2005), the precise mechanism by which its loss contributes to tumor progression is not well understood.…”